Literature DB >> 7873128

Centrally-administered glycine antagonists increase locomotion in monoamine-depleted mice.

B Stauch Slusher1, K C Rissolo, P F Jackson, L M Pullan.   

Abstract

It was shown in the present study that several structurally diverse antagonists of the glycine site of the NMDA receptor, including (R)-HA-966, L689,560, 5,7-dichlorokynurenic acid, 7-chlorokynurenic acid, and two of ZENECA's novel pyridazinoindole glycine antagonists, caused marked reversal of akinesia when administered intrastriatally to monoamine depleted mice. Coinjection of the glycine agonist D-serine antagonized this locomotor stimulation. In addition, all glycine antagonists tested did not cause significant locomotor stimulation when intrastriatally administered to normal mice. These data suggest that glycine antagonists may offer therapeutic utility in the treatment of idiopathic Parkinson's disease.

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 7873128     DOI： 10.1007/bf02336139

Source DB:  PubMed          Journal:  J Neural Transm Gen Sect


  33 in total

1.  MK-801 potentiates dopaminergic D1 but reduces D2 responses in the 6-hydroxydopamine model of Parkinson's disease.

Authors:  M Morelli; G Di Chiara
Journal:  Eur J Pharmacol       Date:  1990-07-17       Impact factor: 4.432

2.  The AMPA receptor antagonist NBQX has antiparkinsonian effects in monoamine-depleted rats and MPTP-treated monkeys.

Authors:  T Klockgether; L Turski; T Honoré; Z M Zhang; D M Gash; R Kurlan; J T Greenamyre
Journal:  Ann Neurol       Date:  1991-11       Impact factor: 10.422

3.  Reversal of experimental parkinsonism by lesions of the subthalamic nucleus.

Authors:  H Bergman; T Wichmann; M R DeLong
Journal:  Science       Date:  1990-09-21       Impact factor: 47.728

Review 4.  The glycine site of the NMDA receptor--five years on.

Authors:  J A Kemp; P D Leeson
Journal:  Trends Pharmacol Sci       Date:  1993-01       Impact factor: 14.819

5.  Selective blockade of N-methyl-D-aspartate (NMDA)-induced convulsions by NMDA antagonists and putative glycine antagonists: relationship with phencyclidine-like behavioral effects.

Authors:  W Koek; F C Colpaert
Journal:  J Pharmacol Exp Ther       Date:  1990-01       Impact factor: 4.030

6.  MK-801 prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in primates.

Authors:  A Zuddas; G Oberto; F Vaglini; F Fascetti; F Fornai; G U Corsini
Journal:  J Neurochem       Date:  1992-08       Impact factor: 5.372

7.  Lack of effect of L-687,414 ((+)-cis-4-methyl-HA-966), an NMDA receptor antagonist acting at the glycine site, on cerebral glucose metabolism and cortical neuronal morphology.

Authors:  R J Hargreaves; M Rigby; D Smith; R G Hill
Journal:  Br J Pharmacol       Date:  1993-09       Impact factor: 8.739

8.  Single-channel conductances of NMDA receptors expressed from cloned cDNAs: comparison with native receptors.

Authors:  P Stern; P Béhé; R Schoepfer; D Colquhoun
Journal:  Proc Biol Sci       Date:  1992-12-22       Impact factor: 5.349

9.  NBQX (6-nitro-sulfamoyl-benzo-quinoxaline-dione) and CPP (3-carboxy-piperazin-propyl phosphonic acid) potentiate dopamine agonist induced rotations in substantia nigra lesioned rats.

Authors:  H Wachtel; M Kunow; P A Löschmann
Journal:  Neurosci Lett       Date:  1992-08-17       Impact factor: 3.046

10.  Interactions between dopamine and amino acid-induced excitation and inhibition in the striatum.

Authors:  L A Chiodo; T W Berger
Journal:  Brain Res       Date:  1986-06-04       Impact factor: 3.252
View more
  3 in total

1.  The glycine antagonist (+)-HA-966 injected into the nucleus accumbens stimulates locomotion in mice. (Rapid communication).

Authors:  M Nilsson; M L Carlsson
Journal:  J Neural Transm (Vienna)       Date:  1997       Impact factor: 3.575

Review 2.  Glutamate receptors as therapeutic targets for Parkinson's disease.

Authors:  Kari A Johnson; P Jeffrey Conn; Colleen M Niswender
Journal:  CNS Neurol Disord Drug Targets       Date:  2009-12       Impact factor: 4.388

Review 3.  Glutamate receptors and Parkinson's disease: opportunities for intervention.

Authors:  Michael J Marino; Ornella Valenti; P Jeffrey Conn
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.